alphamab oncology appoints mr. weihao xu as chief financial officer-凯发88

english 中文简体 中文繁体

alphamab oncology appoints mr. weihao xu as chief financial officer

march 31, 2021 08:10 eastern daylight time

suzhou, china, march 31, 2021 - alphamab oncology (stock code:, appoints mr. weihao xu as chief financial officer, responsible for the company's financial and capital market strategy and investor relations, and report to dr. ting xu, chairman & ceo of alphamab oncology. he will also contribute to global business development and cooperation.

mr. weihao xu has more than 10 years experiences in global capital market, equity investment and financial management. mr. xu held important roles in several publicly traded company and global investment companies. prior to alphamab oncology, mr. xu served as chief financial officer for casi pharmaceuticals and 111 inc. in the area of investment,he served as a portfolio manager in matthews international and several other international funds. mr. xu holds a master of philosophy degree in finance and accounting from columbia business school and also completed high impact cancer research, a postgraduate program at harvard medical school.

dr. ting xu, chairman and ceo of alphamab oncology, commented, “welcome weihao to alphamab oncology. as a portfolio manager and cfo, mr.xu has an in-depth understanding of capital market, dynamics and trends of health industry, especially the biopharmaceutical industry. weihao will strengthen our communication with investors, contribute to the evolving and implementation of the company's strategy, and the global development and business cooperation of our core products. we look forward to propelling the company to the next level, bringing more effective treatment options to cancer patients, and creating higher value for our shareholders.”

mr. weihao xu commented, “alphamab oncology has global leading technology platforms, an innovative product pipeline and expects to launch its first product in 2021.i am very excited to join alphamab at this important value inflection point of the company. as a major investor of alphamab since its ipo, i am deeply impressed by the clinical and r&d progress of the company. i hope to bring my experience in global markets, biotech investment and strategic business development to further propel the growth of the organization. "

about alphamab oncology

alphamab oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.

alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline includes fifteen tumor monoclonal antibodies and bispecific antibodies and a covid-19 multifunctional antibody. four products have advanced into phase i-iii clinical trials or pre-marketing stage in china, the united states, japan and australia. the bla for envafolimab (kn035) has been accepted and granted priority review by the national medical products administration (nmpa).

the company also has state-of-the-art manufacturing capabilities designed and built to meet nmpa and eu/fda’s cgmp standards and a complete quality system which has passed the on-site inspection of an european union qualified person. alphamab oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in china and around the world.

alphamab oncology forward-looking statements

this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.